Search Results

GE HealthCare Plans $945 Million All-Cash Acquisition of Sofie Biosciences: Full-Scale Positioning in the "Final Mile" Delivery of Positron Radiopharmaceuticals and CDMO Capacity

GE HealthCare, the Chicago-based medical imaging and radiodiagnostics giant, has announced that it has entered into a definitive acquisition agreement to acquire radiopharmaceutical company Sofie Biosciences in an all-cash deal valued at $945 million from private equity firm Trilantic North America. The transaction is expected to complete all regulatory approvals and closing procedures by July 2027, and is expected to be accretive to GE HealthCare's revenue growth and adjusted earnings in the first full fiscal year following closing. Founded in 2008 and headquartered in Dulles, Virginia, Sofie Biosciences has built a broad radiopharmaceutical production and distribution network across the United States...

2026-10-08

Best Cyclotron Systems 70MeV high-current proton cyclotron passes factory acceptance test, to be delivered to Taiwan, China

Best Cyclotron Systems (BCS) recently announced that its 70 megaelectronvolt (MeV) high-current proton cyclotron B-70 completed factory acceptance testing in July, and the equipment will soon be delivered to the National Atomic Research Institute (NARI) in Taoyuan City, Taiwan, China. Related installation and project construction are expected to be completed in 2027. According to the introduction, B-70 was designed, developed and manufactured in Canada by engineers and scientists under TeamBest, and is an advanced cyclotron system for high-current proton beam applications. The equipment will be used to expand accelerator-based radioisotope production and research capabilities, and also reflects the company's...

2026-09-11

Ionetix begins routine supply of astatine-211 in North America, expanding sources of isotopes for targeted alpha therapy

Ionetix, a U.S. medical isotope producer, recently announced that it has begun routine supply of astatine-211 (At-211) in North America. The company stated that this development expands the supply sources of At-211 and is expected to support its further application in preclinical research and clinical development. Ionetix noted that it believes it is the first non-academic commercial supplier of At-211 in the United States. Ionetix produces At-211 at its facility in Lansing, Michigan, leveraging its proprietary cyclotron technology. The company currently operates a 30 MeV cyclotron equipped with optimized target technology, aiming to support the production of clinical-grade At-211. The company stated that its production ca...

2026-09-02

Auburn University Installs 200 MeV Superconducting Proton Accelerator to Build First University-Led Space Electronics Radiation Testing Facility in the U.S.

Auburn University's Applied Research Institute has announced the installation of a new 200 MeV superconducting proton accelerator, advancing the construction of the nation's first university-led proton testing facility dedicated to space electronics qualification. The system, a RAD-FX-200 superconducting synchrocyclotron manufactured and installed by Mevion Medical Systems, serves as the core component of Auburn University's new radiation-hardening facility. According to reports, the facility will help address gaps in U.S. space qualification testing capacity, providing radiation testing services for microelectronics to government agencies, aerospace, and defense-related industries. Systems such as satellites, missile defense interceptors, spacecraft, and launch vehicles rely on microelectronics, which may be affected by proton radiation in orbital environments. A single radiation-induced failure can cause system loss, and such failures are typically difficult to repair once in orbit...

2026-08-28

Russia Plans to Complete Development of First Domestic Proton Beam Therapy Cyclotron by 2027

Russian scientists plan to complete the development of the country's first domestically produced proton beam therapy cyclotron by 2027, with commissioning to begin in the same year. This progress was announced by Sergey Gertzog, CEO of the Russian National Institute of Electronics and Atomic Energy (NIIEFA), at the recent Technoprom forum held in Novosibirsk. A proton beam therapy cyclotron is a type of charged particle accelerator that uses magnetic and electric fields to accelerate protons to high-energy states, reaching speeds of one-half to two-thirds the speed of light. The accelerated proton beam can target cancerous tumor areas with relative precision for oncological treatment. According to the schedule outlined in Gertzog's report...

2026-08-28

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21

Cathode High-Voltage Power Supply for CFQS Device ECRH System Manufactured by CNNC Tongchuang Successfully Shipped

On August 3, the cathode high-voltage power supply for the Electron Cyclotron Resonance Heating (ECRH) system of China's first Quasi-Axisymmetric Stellarator (CFQS) device, manufactured by CNNC Tongchuang (Chengdu) Technology Co., Ltd., successfully passed factory acceptance and was officially shipped. The CFQS device is a major scientific and technological infrastructure project of Sichuan Province. The device adopts an advanced quasi-axisymmetric magnetic field configuration, combining the advantages of high confinement performance and steady-state operation. Under low-parameter operating conditions, the CFQS test platform confirmed that the quasi-axisymmetric magnetic field configuration can effectively reduce neoclassical transport losses in plasma and improve plasma confinement, marking the first international experimental verification of the superiority of the quasi-axisymmetric magnetic field configuration. Next, the CFQS stellarator...

2026-08-10

Consolidating Foundations·Sichuan: Accelerated Localization of Nuclear Medical Equipment Benefits the Public

On August 9, 2026, CCTV's "Morning News" program aired a feature titled "Consolidating Foundations·Sichuan: Accelerated Localization of Nuclear Medical Equipment Benefits the Public," reporting on Jiuyiyuan Company. Founded in February 2017, Sichuan Jiuyiyuan Particle Technology Co., Ltd. is a national high-tech enterprise integrating R&D, production, and services of high-end nuclear medical equipment, committed to providing overall solutions for radiopharmaceuticals. A cyclotron is a device that uses magnetic and electric fields to drive charged particles in a circular motion, repeatedly accelerating them via high-frequency electric fields during their movement. Low- and medium-energy cyclotrons applied in the medical field are devices that produce positron-emitting radionuclides, generating a variety of radionuclides that not only meet clinical PET/CT examination needs but also support the clinical positron drug and new drug development demands of the molecular imaging and precision medicine era. The report noted that core nuclear medicine equipment has long relied on imports, which is a key bottleneck constraining the development of nuclear medicine in China. In 2021, Jiuyiyuan successfully developed the first domestically produced medical cyclotron, breaking foreign technological monopoly. In June this year, the company launched the first domestically produced 30MeV multi-particle medium-to-high-energy cyclotron with fully independent intellectual property rights, with mass production planned for September, achieving internationally advanced product performance.

2026-08-10

First Clinical Treatment Successfully Completed with China's Domestic Superconducting Cyclotron Proton Therapy System by CYC-Ion

On the morning of August 7, the domestically developed superconducting cyclotron proton therapy system, independently developed by Hefei CYC-Ion Medical Technology Equipment Co., Ltd., completed the first clinical trial treatment of a subject at Hefei Ion Medical Center. This marks a significant breakthrough as the first domestically produced superconducting cyclotron proton radiation therapy system in China. The subject in this case was a lung cancer patient. The superconducting proton therapy system used in the trial is equipped with the SC240 superconducting cyclotron independently developed by CYC-Ion, featuring an ultra-large irradiation field and 360° full-angle beam delivery capability. The entire treatment process relied on multi-modal fusion 4D image-guided precise positioning, enabling dynamic adaptation and precise treatment. The equipment operated smoothly with low noise, and the treatment control software ran...

2026-08-07

Bolivia Advances Legislative Process for Peaceful Nuclear Technology Applications

EL ALTO, Bolivia, July 29 - The Bolivian Nuclear Energy Agency (ABEN) recently held working exchanges with relevant committees of the Plurinational Legislative Assembly to discuss the reactivation of related legislative agendas, focusing on the continued advancement of Bolivia's nuclear energy program and peaceful nuclear technology application projects. René Soria Sausedo, Executive Director of ABEN, stated that as the primary operating entity of Bolivia's nuclear program, ABEN bears the responsibility of driving the implementation of peaceful nuclear technology application projects. These efforts require modern legal instruments to define institutional mandates, technical standards, and the fundamental legal framework for project development. The parliamentary delegation, led by the President of the International Policy and Migration Protection Committee, visited ABEN facilities...

2026-08-03

Curium Advances Second Cyclotron Investment Plan in Romania to Expand PET Imaging Supply

On July 30, Curium announced that it is advancing its second cyclotron investment plan in Romania to expand access to advanced nuclear medicine services locally and further strengthen healthcare infrastructure. According to the introduction, after completing assessments of market opportunities, technical requirements, and regional infrastructure, Curium has identified the Cluj-Napoca region as the preferred site for the project and selected a preferred local partner. Preparatory work is currently underway to support the project's progression to the next phase. This expansion plan aims to increase relevant production capacity, enhance PET imaging equipment and service supply capabilities, improve patient access to advanced diagnostic procedures, and support the...

2026-07-30